+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients

Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients

Blood 91(12): 4472-4479, June 15

We have studied the cellular and molecular responses to long-term hydroxyurea (HU) treatment in 29 severely affected young patients with sickle cell disease (mean age, 10.9 +- 4.1 years). Patients received HU at 20 mg/kg/d on 4 consecutive days per week initially, with a monthly escalated dose avoiding marrow-toxicity (mean steady-state dose, 34.2 +- 4.6 mg/kg/d) for 12 to 36 months (mean duration, 22 months). The studied parameters were hemoglobin F (HbF), F reticulocytes (F retics), F cells, the amount of HbF per F cell (F/F cell), polymer tendency at 40% and 70% oxygen saturation, and hemolysis. Initial HbF (Fi) was dispersed (from 0.85% to 13.9%). HbF increased in all patients but 1. HbF at maximal response (Fmax) reached a sustained level varying from a 1.5-fold to a 16-fold Fi after a variable delay (6 to 24 months). Fmax was not related to HU dosage, but DELTAF (Fmax - Fi) was strongly correlated to DELTAMCV (MCVmax - MCVi). HbF increase resulted from the increase of both F cells and F/F cell. In this rather short series, Fi and Fmax were not significantly associated with age, gender, or beta-globin haplotype. Neither Fmax nor DELTAF was related to bone marrow reserve, as measured by baseline reticulocyte or neutrophil counts. However, Fmax was highly dependent on Fi. When patients are individualized into three groups according to Fmax (group 1, Fmax >20% (12 patients); group 2, 10% < Fmax < 20% (11 patients); group 3, Fmax <10% (5 patients)), Fi is significantly different between groups, being the highest in group 1. In addition, the best responders (group 1) were significantly different from patients in the two other groups with higher levels of total hemoglobin, decreased bilirubin, and decreased polymer tendency.

(PDF emailed within 1 workday: $29.90)

Accession: 008683345

Download citation: RISBibTeXText

Related references

Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease. Blood 91(12): 4472-4479, 1998

Long-term hydroxyurea treatment in young sickle cell patients. Current Opinion in Hematology 6(2): 115-120, 1999

Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience. Seminars in Oncology 19(3 Suppl 9): 67-73, 1992

Rheological properties of sickle erythrocytes in patients with sickle cell anaemia: the effect of hydroxyurea, fetal hemoglobin and α-thalassaemia. European Journal of Haematology: -, 2018

Induction of fetal hemoglobin in sickle cell patients by hydroxyurea: the N.I.H. experience. Progress in Clinical and Biological Research 316b: 281-293, 1989

Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients. Hemoglobin 35(1): 13-21, 2011

Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood 89(3): 1078-1088, 1997

Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 69(1): 109-116, 1987

Hydroxyurea frequently induces fetal hemoglobin synthesis in sickle cell patients after a lag period. Clinical Research 37(2): 386A, 1989

A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Expert Review of Hematology 8(5): 669-679, 2016

Effect of hydroxyurea on G gamma chain fetal hemoglobin synthesis by sickle-cell disease patients. Brazilian Journal of Medical and Biological Research 36(10): 1289-1292, 2003

Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood 114(21): 4639-4644, 2010

Cellular parameters of fetal hemoglobin response and predicted hemoglobin S polymerization in sickle cell children treated with hydroxyurea. Blood 84(10 SUPPL 1): 414A, 1994

Nitric oxide metabolites, cGMP, and fetal hemoglobin levels in sickle cell patients receiving hydroxyurea A pharmacodynamic study. Blood 98(11 Part 1): 489a-490a, November 16, 2001

Augmentation of fetal hemoglobin levels by low-dose short-duration 5-Aza-2-deoxycytidine administration in sickle cell anemia patients who had no HbF elevation following hydroxyurea therapy. Blood 92(10 SUPPL 1 PART 1-2): 30B, Nov 15, 1998